Leukapheresis Market

The leukapheresis market was estimated to be worth USD 90.6 million in 2026 and is poised to reach USD 138.7 million by 2031, growing at a CAGR of 8.9%. The leukopaks market was estimated to be worth USD 432.1 million in 2026 and is poised to reach USD 1,883.9 million by 2031, growing at a CAGR of 34.2%.

The global leukapheresis market is witnessing steady growth due to several concerns, like increasing cases of leukemia, the quick ramp-up of cell and gene therapy programs, and broader use of leukapheresis as the vital first step in both autologous and allogeneic cell therapy manufacturing. A notable rise in CAR, T therapy approvals, an increase in clinical pipelines, and research into T-cells, NK-cells, and dendritic cells contribute extensively to the global increase in procedure volumes. Innovations in apheresis machines, a move to automated and GMP-compliant cell collection platforms, as well as the repeated demand for single-use leukoreduction kits and consumables, have a growing impact on the market's steady expansion. Considerable investments in cell therapy manufacturing facilities in North America, Europe, and Asia Pacific, as well as the increasing collaborations between hospitals, blood centers, and biopharmaceutical companies, are some of the factors that are globally ramping up the use of leukapheresis.

To know about the assumptions considered for the study download the pdf brochure

In April 2023, Fresenius Kabi, Germany, upgraded its Amicus Blue Extracorporeal Photopheresis (ECP) by improving the software versions, along with the single-use, flexible, disposable kits. This improves the efficiency of the process for the procedures of leukapheresis and photopheresis.
Charles River Laboratories International, Inc. (US) launched the CliniPrime Fresh Leukopak line in January 2023. This offering includes GMP-grade cellular starting material. This helps those developing cell and gene therapies with their leukopaks.

The major players in the leukapheresis market include Fresenius Kabi (Germany), Terumo BCT (Japan), Haemonetics Corporation (US), Grifols S.A. (Spain), Macopharma (France), Medica S.p.A. (Italy), Miltenyi Biotec (Germany), Baxter International Inc. (US), Nikkiso Co., Ltd. (Japan), Immune Therapy Holdings AB (Sweden), SCTbio (Czech Republic), Biohope Scientific SL (Spain), and Caltag Medsystems Ltd. (UK)

Fresenius Kabi (Germany)

Fresenius Kabi is a major participant in the leukapheresis market. This can largely be attributed to its extensive network of hospital collaborations and its diversified range of apheresis products. Fresenius Kabi's products comprise its leukapheresis systems and single-use devices. These are largely preferred by hematology and oncology treatment facilities and transfusion stations. Its emphasis on system development and European regulations will serve it well in therapeutic leukapheresis as well as cell and gene therapies.

Terumo BCT (Japan)

Terumo BCT has a strong global foothold on account of its advanced continuous flow apheresis system and also penetration in blood centers and hospitals. Terumo is an essential part of supporting leukapheresis for therapeutic purposes and also immune cell harvest for the purpose of cell and gene therapy. Its continued focus on training initiatives and collaboration efforts gives it strong growth potential in this market.

Haemonetics Corporation (US)

Haemonetics has emerged as an established player in the leukapheresis market through its automated apheresis systems. These systems are efficient and reliable. They are used extensively by hospitals and blood banks for leukoreduction and cell harvesting. The company's sustained investment in workflow automation, donor safety, and collection consistency is well-placed in consideration of the rising global trend to standardize and ensure GMP compliance in cell collection procedures. This major focus has thus led to the global recognition of Haemonetics systems, facilitating both therapeutic and research-based leukapheresis in North America, Europe, Asia Pacific, and other emerging markets.

Market Ranking

The leukapheresis market is a moderately consolidated market, which is largely occupied by the following market players: Fresenius Kabi, Terumo BCT, Haemonetics, Macopharma, and Grifols. Fresenius Kabi, along with Terumo BCT, holds a strong market position due to its installed base in hospitals and blood centers. Key market players, including Fresenius Kabi, Terumo BCT, Haemonetics, Macopharma, and Grifols, are adopting strategies like improving products continuously, adding products like single-use disposables, and collaborations with cell and gene therapy innovators, among others.

Related Reports:

Leukapheresis Market by Type (Filter, Membrane Separator, Centrifugal Device), Leukopak (Mobilized, Isolated PBMC), Application (Research [Cell & Gene Therapy, Transplantation], Therapeutic), Indication, End User, Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com